These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3326450)

  • 1. [Can diabetic nephropathy be prevented? Or what is the point of no return?].
    Grimaldi A; Baumelou A
    Ann Med Interne (Paris); 1987; 138(7):483-5. PubMed ID: 3326450
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention and treatment of diabetic nephropathy.
    Wittmann I; Molnár GA; Degrell P; Wagner Z; Tamaskó M; Laczy B; Brasnyó P; Wagner L; Nagy J
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S36-42. PubMed ID: 15955373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glycosaminoglycans in diabetic nephropathy].
    Olszowska A
    Pol Merkur Lekarski; 2000 Dec; 9(54):873-5. PubMed ID: 11255659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diabetic nephropathy].
    Körner A
    Orv Hetil; 1985 Jul; 126(28):1701-5. PubMed ID: 3936000
    [No Abstract]   [Full Text] [Related]  

  • 5. Early diabetic nephropathy: detection and prevention.
    Viberti G; Bending JJ
    Adv Nephrol Necker Hosp; 1988; 17():101-11. PubMed ID: 3124534
    [No Abstract]   [Full Text] [Related]  

  • 6. Going out to detect incipient diabetic nephropathy rather than waiting until it has supervened--a reversal in policy.
    Parving HH
    Nephrol Dial Transplant; 1996 Sep; 11(9):1728-9. PubMed ID: 8918612
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antidiabetic agents and renal insufficiency].
    Robles NR; Blanco J
    Nefrologia; 2002; 22(4):325-8. PubMed ID: 12369123
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent advances in diabetic nephropathy.
    Marshall SM
    Postgrad Med J; 2004 Nov; 80(949):624-33. PubMed ID: 15537844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current guidelines for the prevention and treatment of diabetic nephropathy. International Diabetes Federation].
    Bilo HJ
    Ned Tijdschr Geneeskd; 1995 Sep; 139(36):1847-9. PubMed ID: 7477510
    [No Abstract]   [Full Text] [Related]  

  • 10. The CARI guidelines. Prevention and management of chronic kidney disease in type 2 diabetes.
    Chadban S; Howell M; Twigg S; Thomas M; Jerums G; Cass A; Campbell D; Nicholls K; Tong A; Mangos G; Stack A; MacIsaac RJ; Girgis S; Colagiuri R; Colagiuri S; Craig J;
    Nephrology (Carlton); 2010 Apr; 15 Suppl 1():S162-94. PubMed ID: 20591029
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Can diabetic nephropathy be prevented?].
    Viberti GC; Wiseman M; Mackintosch D; Keen H
    Journ Annu Diabetol Hotel Dieu; 1983; ():79-88. PubMed ID: 6358621
    [No Abstract]   [Full Text] [Related]  

  • 13. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microalbuminuria and mortality in type 2 diabetes.
    Strayer SM
    J Fam Pract; 1998 Aug; 47(2):89-90. PubMed ID: 9722786
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetic nephropathy.
    Bloomgarden ZT
    Diabetes Care; 2008 Apr; 31(4):823-7. PubMed ID: 18375432
    [No Abstract]   [Full Text] [Related]  

  • 16. ACE inhibitors as a shield against diabetic nephropathy.
    Materson BJ
    Arch Intern Med; 1996 Feb; 156(3):239-40. PubMed ID: 8572832
    [No Abstract]   [Full Text] [Related]  

  • 17. [The kidney as a target organ in diabetic patients with arterial hypertension].
    Viberti G
    Drugs; 2003; 63 Spec No 1():31-7. PubMed ID: 12708880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
    Clark WF; Churchill DN; Forwell L; Macdonald G; Foster S
    CMAJ; 2000 Jan; 162(2):195-8. PubMed ID: 10674051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical problems in the management of hypertension in the diabetic patient.
    O'Hare JP
    J Diabetes Complications; 1996; 10(3):146-8. PubMed ID: 8807462
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.